AIDS THERAPIES

艾滋病治疗

• 批准号: 6116347
• 负责人: Che-Chung Tsai
• 金额: $ 8.67万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-05-01 至 2000-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6116347
• 关键词: AIDS; Mammalia; Primates; cardiovascular system; clinical research; clinical trials; drug adverse effect; immunology; infection; inflammation; lymphatic system; orphan disease /drug; urinary tract; virus

The SIV model (both in vitro and in vivo) is excellent for testing HIV drug therapies owing to the similarities between SIVmne and HIV in structure, genomic organization, and disease production. The goal of this project is to develop an effective antiviral therapy to either prevent or cure AIDS in macaques. Ultimately, this information may be applied to AIDS in humans. In 1997 we continued a clinical trial using preexposure and postexposure prophylaxis of an acyclic nucleoside phosphonate, (R)-9-(2-phosphonylmethoxyethl)adenine (PMPA), against acute SIV infection in longtailed macaques. PMPA prevented the establishment of SIV infection when a 28-day treatment was initiated 24 h after intravenous virus inoculation with SIV (100% infectious dose). All untreated, inoculated macaques became infected with SIV.

SIV模型（体外和体内）非常适合测试由于Sivmne和HIV在结构，基因组组织和疾病产生中的相似性，因此测试HIV药物疗法。 该项目的目的是开发有效的抗病毒疗法，以预防或治愈猕猴。 最终，这些信息可以应用于人类的援助。 在1997年，我们继续使用临床试验，使用前暴露和曝光后预防偶联核苷，（R）-9-（2-磷酸氯甲基氧基）腺嘌呤（PMPA）（PMPA），以抗急性SIV感染在长尾毛虫中。 PMPA在静脉注射SIV接种后24小时（100％感染剂量）在28天治疗（100％感染剂量）后，阻止了SIV感染的建立。 所有未经处理的接种猕猴都被SIV感染了。